Disease · MONDO_0100073
methicillin-resistant staphylococcus aureus infectious disease
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. methicillin-resistant staphylococcus aureus infectious disease. Diseases, record MONDO_0100073. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0100073
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- methicillin-resistant staphylococcus aureus infectious disease
- Open Targets ID
- MONDO_0100073
- Other names
Infection, MRSA, MRSA, MRSA bacteremia, MRSA bacteremias, MRSA infection, Methicillin-Resistant Staphylococcus Aureus Infection, Methicillin-resistant Staphylococcus aureus (MRSA) infection, infection by MRSA, methicillin-resistant Staphylococcus aureus (MSSA) bacteremia
- Highest stage of its drugs
- Phase 3, for 9 of its 24 drugs, from ClinicalTrials.gov and TTD
Source Open Targets
Drugs24
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| VANCOMYCIN | CHEMBL262777 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 9 | 9 | Drugs and targets |
| TRIMETHOPRIM | CHEMBL22 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| CO-TRIMOXAZOLE | CHEMBL58061 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 0 | Drugs and targets |
| LINEZOLID | CHEMBL126 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TELAVANCIN | CHEMBL507870 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| LEVONADIFLOXACIN | CHEMBL190561 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 1 | 1 | Drugs and targets |
| AUROGRAB | CHEMBL2109569 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| TIGECYCLINE | CHEMBL376140 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FUSIDIC ACID | CHEMBL374975 | Small molecule | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
| MUPIROCIN | CHEMBL719 | Small molecule | Phase 2 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
1 to 10 of 24
See all 24 drugsTargets7
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GUCY1A1 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 2 | https://conductscience.org/library/genes/2982 | Drugs and targets |
| GUCY1A2 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 2 | https://conductscience.org/library/genes/2977 | Drugs and targets |
| GUCY1B1 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 2 | https://conductscience.org/library/genes/2983 | Drugs and targets |
| MMP1 | Interstitial collagenase | 1 | Matrix metalloproteinase-1 inhibitor | Phase 2 | https://conductscience.org/library/genes/4312 | Drugs and targets |
| MMP13 | Collagenase 3 | 1 | Matrix metalloproteinase 13 inhibitor | Phase 2 | https://conductscience.org/library/genes/4322 | Drugs and targets |
| MMP7 | Matrilysin | 1 | Matrix metalloproteinase 7 inhibitor | Phase 2 | https://conductscience.org/library/genes/4316 | Drugs and targets |
| MMP8 | Neutrophil collagenase | 1 | Matrix metalloproteinase 8 inhibitor | Phase 2 | https://conductscience.org/library/genes/4317 | Drugs and targets |
Trials23
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00107978 | Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus | Phase 3 | 1,035 | 2010-02-01 | Staphylococcal Skin Infection | TELAVANCIN, VANCOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT00666276 | Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan) | 1,004 | 2012-07-02 | Staphylococcal Infections | LINEZOLID | Its record names the disease | ClinicalTrials.gov | |
| NCT00091819 | Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus | Phase 3 | 862 | 2009-12-08 | Staphylococcal Skin Infection | TELAVANCIN, VANCOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT01162733 | Loading Vancomycin Doses in the Emergency Department | Not applicable | 99 | 2014-03-13 | Infectious Disease | VANCOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT02063867 | Active Bathing to Eliminate Infection (ABATE Infection) Trial | Not applicable | 53 | 2019-07-12 | Healthcare Associated Infections, Methicillin Resistant Staphylococcus Aureus, Multi Drug Resistant Organisms | CHLORHEXIDINE, MUPIROCIN | Its record names the disease | ClinicalTrials.gov |
| NCT01349192 | Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF) | Phase 2 | 47 | 2017-05-15 | Cystic Fibrosis, Methicillin-resistant Staphylococcus Aureus | CHLORHEXIDINE, CHLORHEXIDINE GLUCONATE, MINOCYCLINE, MUPIROCIN, RIFAMPIN, SULFAMETHOXAZOLE, TRIMETHOPRIM | Its record names the disease | ClinicalTrials.gov |
| NCT01594827 | Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP) | Phase 2 | 29 | 2018-11-20 | Cystic Fibrosis | DOXYCYCLINE, MUPIROCIN, RIFAMPIN, TRIMETHOPRIM, VANCOMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT05225805 | Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis | Phase 1 | 13 | 2024-06-17 | Cystic Fibrosis | LEFAMULIN | Its record names the disease | ClinicalTrials.gov |
| NCT04793152 | Vancomycin Dosing for Serious MRSA Infections: A Non-inferiority Randomized Trial of Trough Level Versus AUC/MIC | Not applicable | 700 | MRSA | VANCOMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT03405064 | Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI) | Phase 3 | 501 | Acute Bacterial Skin and Skin Structure Infections | LEVONADIFLOXACIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 23
See all 23 trialsComparisons in its trials22
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm 2: Decolonization vs Arm 1: Usual Care: deaths from any cause | 0 of 183,013 | 0 of 156,889 | 339,902 | NCT02063867 | Trial comparisons |
| Arm 2: Decolonization vs Arm 1: Usual Care: serious adverse events | 0 of 183,013 | 0 of 156,889 | 339,902 | NCT02063867 | Trial comparisons |
| Telavancin vs Vancomycin: serious adverse events | 38 of 503 | 15 of 509 | 1,012 | NCT00107978 | Trial comparisons |
| Linezolid-without Concomitant Drugs vs Linezolid-with Concomitant Drugs: Factors Considered to Affect the Safety of Linezolid - Concomitant Drugs. | 9 of 97 | 154 of 873 | 970 | NCT00666276 | Trial comparisons |
| Linezolid Without Renal Dysfunctions vs Linezolid- With Renal Dysfunctions: Factors Considered to Affect the Safety of Linezolid - Renal Dysfunctions. | 125 of 765 | 38 of 205 | 970 | NCT00666276 | Trial comparisons |
| Linezolid-without Hepatic Dysfunctions vs Linezolid- With Hepatic Dysfunctions: Factors Considered to Affect the Safety of Linezolid - Hepatic Dysfunctions. | 137 of 856 | 26 of 114 | 970 | NCT00666276 | Trial comparisons |
| Linezolid-administrated Over 15 Days vs Linezolid-administrated Less Than 15 Days: Factors Considered to Affect the Safety of Linezolid - Duration of Drug Administration. | 53 of 203 | 110 of 767 | 970 | NCT00666276 | Trial comparisons |
| Linezolid-without Non-drug Therapies vs Linezolid-with Non-drug Therapies: Factors Considered to Affect the Safety of Linezolid - Non-drug Therapies. | 87 of 610 | 76 of 360 | 970 | NCT00666276 | Trial comparisons |
| Linezolid-male vs Linezolid-female: Factors Considered to Affect the Safety of Linezolid - Gender. | 109 of 662 | 54 of 308 | 970 | NCT00666276 | Trial comparisons |
| Linezolid-over 65 vs Linezolid-less Than 65: Factors Considered to Affect the Safety of Linezolid - Age | 122 of 688 | 41 of 282 | 970 | NCT00666276 | Trial comparisons |
1 to 10 of 22
See all 22 comparisons in its trialsPapers from its trials10
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100073
GET https://conductscience.org/api/diseases/v1/MONDO_0100073/drugs?page=2